Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
$33.98+0.05 (+0.15%)
Close on Nov 13, 2026Market cap $2.24BP/E 6.3Yield –
Lakefront Biotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Lakefront Biotherapeutics's enterprise value was $2.10B on Nov 11, 2026, against $1.99B a year earlier. Over the last 5 years it ranged from $299.43M to $2.22B, with a median of $1.77B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.10B | +0.9% |
| 2025 | Dec 31, 2025 | $2.08B | +26.9% |
| 2024 | Dec 31, 2024 | $1.64B | -22.3% |
| 2023 | Dec 29, 2023 | $2.11B | +307.4% |
| 2022 | Dec 30, 2022 | $517.63M | -13.2% |
| 2021 | Dec 31, 2021 | $596.65M | -78.6% |
| 2020 | Dec 31, 2020 | $2.79B | -70.6% |
| 2019 | Dec 31, 2019 | $9.49B | +186.1% |
| 2018 | Dec 31, 2018 | $3.32B | +1.6% |
| 2017 | Dec 29, 2017 | $3.27B | +69.0% |
| 2016 | Dec 30, 2016 | $1.93B | – |
See a number that looks wrong?